Melatonin and magnesium in polycystic ovary syndrome

Phase 3

Recruiting

• Conditions: Polycystic Ovarian syndrome.; Polycystic ovarian syndrome; E28.2

• Registration Number: IRCT20191130045556N1
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 February 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 84

Inclusion Criteria

Patients with polycystic ovary syndrome based on Rotterdam criteria
Age 18-40 years
BMI=35
Tendency to participate in the study

Exclusion Criteria

Pregnancy
Lactation
Sleeping disorders
The night shift workers
???Any disease that affects metabolic parameters in this trial including Cushing's Syndrome, hypoglycemia, type I or II Diabetes, androgen secreting tumors or congenital adrenal hyperplasia, hyperprolactinemia, hyperparathyroidism, Thyroid disorders, hypertension, Anemia, Allergy, Asthma, Cardiovascular, Kidney, Liver or Pulmonary diseases, Cancer
Any drugs that may cause side effects such as menstrual disorders, hirsutism or acne or drugs that affect plasma androgen levels, lipid profile, blood glucose or inflammatory factors during the last 3 months (such as oral contraceptives (OCP), Ovulation induction, anti-androgenic, insulin-sensitizer, blood glucose lowering, anti-obesity, antidepressants, anti-coagulants, Thiazides, Corticosteroids, Metformin, Lipid lowering, NSAIDs, Aspirin)
Following the special diet
Weight loss of more than 5% body weight in the last 6 months Taking melatonin, magnesium, antioxidant and/or anti-inflammatory supplements within 3 months prior to the enrollment
Taking melatonin, magnesium, antioxidant and/or anti-inflammatory supplements within 3 months prior to the enrollment
Smoking
Alcohol consumption
Migration
Unwillingness to continue cooperation

Study & Design

• Study Type: interventional
• Study Design: Not specified